Skip to content Skip to sidebar Skip to footer
Menu
Menu
Newsletter
Menu
Newsletter
Compumedics
Growth Stocks Healthcare Stocks Undervalued Stocks
Compumedics (ASX:CMP): Expecting $70m sales but trading at barely over 1x Revenues, is this a buy?
Some investors may think Compumedics (ASX:CMP) is highly undervalued. It trades at $75m, a level that many clinical-stage medtech or biotech stocks are trading well above...but Compumedics is a commercial-stage company expecting nearly that amount of sales for an entire year.What's the story here? What are the Best ASX stocks to invest in right now? Check…
January 27, 20260Comments
Airwallex
Tech Stocks Technology
Airwallex: Will this Australian-born fintech IPO in 2026? There were high hopes, but these may have been dashed
Investors speculate about which private companies could IPO and Airwallex has been one of the most commonly mentioned names. The decade-old fintech completed two US$300m funding rounds during 2025 with the latter valuing it at US$8bn (A$12bn).Although it does not have to disclose its full financials as a private company, the company has indicated that…
January 23, 20260Comments
Fisher and Paykel
Blue Chip Stocks Healthcare Stocks
Fisher and Paykel (ASX:FPH): It exports sleep apnea products to 120 countries, but here’s why ResMed is a better buy
If there was one ASX company brutally honest about the fact that it could not escape an impact from Trump's tariffs, it was Fisher and Paykel (ASX:FPH). Of course, this was not just because of the tariffs themselves but forex movements and the economic environment.FPH shares fell over 15% in just two months from mid-January…
January 22, 20260Comments
ideas for the Australian capital markets
Uncategorized
5 radical ideas for the Australian capital markets from North America that could reinvigorate investor sentiment
Our article title '5 radical ideas for the Australian capital markets from North America what could reinvigorate investor sentiment' may cause some raised eyebrows. Do we really just want to 'copy North America'? Is investor sentiment really that bad that we need 'radical ideas' to reinvigorate investor sentiment? Didn't the ASX rise 6% in 2025?Look,…
January 21, 20260Comments
Epiminder
Biotech Stocks Healthcare Stocks Life Sciences
Epiminder (ASX:EPI): Less than 2 months since its IPO, this medtech made its first implant
Epiminder (ASX:EPI) only listed on the ASX at the end of November last year, but just announced to market that it completed the first implant of its Minder system in the USA.The company's Minder system is an epilepsy monitoring technology which is in a global clinical trial which will enrol over 200 patients. Shares only…
January 21, 20260Comments

the Kick-ass Multipurpose WordPress Theme

Investing in the Year of the Rat
2020, the Golden Year
Market trouble spots to avoid in 2020
© 2026 Kicker. All Rights Reserved.

Add Your Heading Text Here